Document is current
Any future updates will be listed below
-
Authors
Daly, R. Paola
Jalbert, Jessica J.
Keith, Shannon
Symonds, Tara
Shammo, Jamile
-
Funding
Funding for this research was provided by:
Regeneron Pharmaceuticals (RG1017)
- License Information
-
More Information
Article History
Received: 27 May 2021
Accepted: 15 September 2021
First Online: 28 September 2021
Declarations
:
: This study was performed in accordance with the Declaration of Helsinki and was approved by the Copernicus Group IRB, Panel 18 (07-Nov-2020) CGIBR protocol # 20182896.
:
: R.P.D. was an employee of Clinical Outcomes Solutions; J.J.J. is an employee of Regeneron Pharmaceuticals, Inc.; S.K. and T.S. are employees of Clinical Outcomes Solutions; J.S. has the following disclosures: Regeneron Pharmaceuticals, Inc.: Consultancy; Incyte: Consultancy, Honoraria, Research Funding, Speakers Bureau; CTI Pharma: Research Funding; Onconova: Research Funding; Alexion: Consultancy, Honoraria, Research Funding, Speakers Bureau; Celgene: Consultancy, Honoraria, Research Funding, Speakers Bureau; Apellis: Membership on an entity's Board of Directors or advisory committees; Otsuka: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Astex Pharma: Research Funding; Sanofi: Consultancy, Honoraria, Speakers Bureau.
